BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revolade eltrombopag regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Revolade eltrombopag in its approved indications - to treat chronic idiopathic thrombocytopenic purpura (ITP) in splenectomized patients who are refractory to other treatments and as a second-line treatment of non-splenectomized patients...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >